
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is a profitable company with a strong financial foundation and a growing global market reach in the diabetes technology industry. The company has shown resilience in the face of challenges and has a strong potential for future growth and success. Their focus on innovation and established partnerships make them a favorable investment choice.
Bears say
Minimed Group is a medical technology firm with a negative outlook, as they face intense competition in the diabetes technology market and potential regulatory and pricing risks. Despite a strong product pipeline and global reach, they may struggle to maintain market share and margins as other players enter the market. While their recent revenue growth and portfolio refresh are positive signs, concerns over reimbursement and pricing may continue to weigh on the company. Additionally, their high valuation and potential delays in product timelines may limit potential upside for investors.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares